These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17061981

  • 1. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
    Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, Christal J, Chen CF, Nichol JL.
    Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
    [Abstract] [Full Text] [Related]

  • 2. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
    Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL.
    N Engl J Med; 2006 Oct 19; 355(16):1672-81. PubMed ID: 17050891
    [Abstract] [Full Text] [Related]

  • 3. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
    Nichol JL.
    Pediatr Blood Cancer; 2006 Oct 15; 47(5 Suppl):723-5. PubMed ID: 16933266
    [Abstract] [Full Text] [Related]

  • 4. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
    Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP.
    Int J Hematol; 2009 Sep 15; 90(2):157-165. PubMed ID: 19543952
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study.
    Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, Arai Y, Sonehara Y, Nichol JL.
    J Clin Pharmacol; 2007 Dec 15; 47(12):1489-97. PubMed ID: 17925591
    [Abstract] [Full Text] [Related]

  • 6. Romiplostim: a novel thrombopoiesis-stimulating agent.
    Perreault S, Burzynski J.
    Am J Health Syst Pharm; 2009 May 01; 66(9):817-24. PubMed ID: 19386944
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
    Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL.
    Blood; 2009 Mar 05; 113(10):2161-71. PubMed ID: 18981291
    [Abstract] [Full Text] [Related]

  • 8. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT, Viallard JF, Nurden P.
    Lancet; 2009 May 02; 373(9674):1562-9. PubMed ID: 19324405
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immune thrombocytopenic purpura--the changing therapeutic landscape.
    Bromberg ME.
    N Engl J Med; 2006 Oct 19; 355(16):1643-5. PubMed ID: 17050888
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
    Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL.
    Lancet; 2008 Feb 02; 371(9610):395-403. PubMed ID: 18242413
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.
    Wang B, Nichol JL, Sullivan JT.
    Clin Pharmacol Ther; 2004 Dec 02; 76(6):628-38. PubMed ID: 15592334
    [Abstract] [Full Text] [Related]

  • 14. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial.
    Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL.
    Clin Ther; 2007 May 02; 29(5):950-962. PubMed ID: 17697914
    [Abstract] [Full Text] [Related]

  • 15. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
    Pullarkat VA, Gernsheimer TB, Wasser JS, Newland A, Guthrie TH, de Wolf JT, Stewart R, Berger D.
    Am J Hematol; 2009 Aug 02; 84(8):538-40. PubMed ID: 19569197
    [No Abstract] [Full Text] [Related]

  • 16. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ.
    Eur J Haematol Suppl; 2008 Feb 02; (69):9-18. PubMed ID: 18211568
    [Abstract] [Full Text] [Related]

  • 17. Romiplostim management of immune thrombocytopenic purpura.
    Ipema HJ, Jung MY, Lodolce AE.
    Ann Pharmacother; 2009 May 02; 43(5):914-9. PubMed ID: 19401474
    [Abstract] [Full Text] [Related]

  • 18. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
    Tiu RV, Sekeres MA.
    Expert Opin Biol Ther; 2008 Jul 02; 8(7):1021-30. PubMed ID: 18549331
    [Abstract] [Full Text] [Related]

  • 19. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
    Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S.
    Thromb Haemost; 2008 Jan 02; 99(1):4-13. PubMed ID: 18217129
    [Abstract] [Full Text] [Related]

  • 20. [Romplostim in the treatment of immune thrombocytopenic purpura at a tertiary hospital].
    Riu Viladoms G, Creus Baró N, Estefanell Tejero A, Ribas Sala J.
    Farm Hosp; 2012 Jan 02; 36(5):434-7. PubMed ID: 22871365
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.